培美曲塞二线治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Pemetrexed as the Second-line Treatment for Advanced Non-small Cell Lung Cancer

作　　者：彭丽萍[1] 张倞 吴克雄[1] 高丽霞[1] 

机构地区：[1]新疆克拉玛依市中心医院肿瘤科,834000 [2]新疆克拉玛依市天山社区卫生所,834000

出　　处：《实用癌症杂志》2013年第3期295-297,共3页The Practical Journal of Cancer

摘　　要：目的评价单药培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法经病理学或细胞学确诊,一线化疗后出现复发或进展的晚期NSCLC患者23例。单药培美曲塞500 mg/m2,第1天,21 d为1个周期。完成2个周期以上化疗评价疗效和不良反应。结果 23例中无CR病例,PR 4例,SD 13例,PD 6例,有效率(CR+PR)为17.4%(4/23),临床获益率为(CR+PR+SD)73.9%(17/23),中位生存期(MST)8.3个月。不良反应主要为骨髓抑制和消化道反应。结论培美曲塞二线治疗晚期NSCLC安全有效,耐受性好。Objective To evaluate the efficacy and adverse effects of pemetrexed as the second-line treatment for advanced non-small cell lung cancer（NSCLC）.Methods Confirmed by pathology or cytology,23 patients with advanced or progressive NSCLC after the first line chemotherapy treatment were detected.All patients were given pemetrexed 500 mg.m-2 on the first day,21 days as a cycle.The efficacy and adverse reactions of chemotherapy after 2 cycles were evaluated.Results There was no case with complete response.4 cases had partial response,13 had stable disease and 6 progressive disease.The overall response rate was 17.4%.The clinical benefit rate was 73.9%,median survival time（MST）was 8.3 months.The common adverse effects were leucopenia and gastrointestinal response.Conclusion Pemetrexed is effective and feasible as the second-line treatment for advanced NSCLC

关 键 词：培美曲塞 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]